Cleared Traditional

K081361 - CHEMOCLAVE CYTOTOXIC MEDICATION PREPARATION AND DELIVERY SYSTEM, MODEL, CH-XXXX

K081361 is an FDA 510(k) clearance for CHEMOCLAVE CYTOTOXIC MEDICATION PREPARA..., manufactured by Icu Medical, Inc.. The device is a Class 2 General Hospital device with product code FPA cleared through the Traditional 510(k) pathway after a 105-day FDA review.

K081361 · Icu Medical, Inc. · General Hospital
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 2008
Decision
105d
Days
Class 2
Risk

K081361 is an FDA 510(k) clearance for the CHEMOCLAVE CYTOTOXIC MEDICATION PREPARATION AND DELIVERY SYSTEM, MODEL, CH-XXXX. Classified as Set, Administration, Intravascular (product code FPA), Class II - Special Controls.

Submitted by Icu Medical, Inc. (Salt Lake City, US). The FDA issued a Cleared decision on August 28, 2008 after a review of 105 days - within the typical 510(k) review window.

This device falls under the General Hospital FDA review panel, regulated under 21 CFR 880.5440 - the FDA general hospital device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the General Hospital review framework, consistent with the majority of Class II 510(k) submissions.

View all Icu Medical, Inc. devices

FDA 510(k) Submission Details - K081361

510(k) Number K081361 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 15, 2008
Decision Date August 28, 2008
Days to Decision 105 days
Submission Type Traditional
Review Panel General Hospital (HO)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
24d faster than avg
Panel avg: 129d · This submission: 105d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

FPA Device Classification - Class 2, Special Controls

Product Code FPA Set, Administration, Intravascular
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 880.5440
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most General Hospital devices follow this clearance model.

Regulatory Peers - FPA Set, Administration, Intravascular

All 749
Devices cleared under the same product code (FPA) and FDA review panel - the closest regulatory comparables to K081361.
MISER CONTRAST MANAGEMENT SYSTEM
K083576 · Merit Medical Systems, Inc. · Dec 2008
NEXUS I.V. NEEDLESS ACCESS CANNULA FOR INTRAVASCULAR ADMINISTRATION SETS
K081123 · Nexus Medical, LLC · Nov 2008
NIPRO SAFETOUCH HUBER INFUSTION SET
K081210 · Nipro Medical Corp. · Oct 2008
POWERLOC CLEAR SAFETY INFUSION SET
K082306 · C.R. Bard, Inc. · Aug 2008
UNASSIGNED
K080544 · Medcomp · Aug 2008
ANTIMICROBIAL ULTRASITE VALUE, ULTRASITE AG
K073396 · B.Braun Medical, Inc. · Aug 2008